| (Values in U.S. Thousands) | Sep, 2023 | Jun, 2023 | Mar, 2023 | Dec, 2022 | Sep, 2022 |
| Sales | 10 | 620 | 0 | 0 | 0 |
| Sales Growth | -98.39% | unch | unch | unch | unch |
| Net Income | -12,090 | -13,680 | 1,170 | -23,000 | -14,890 |
| Net Income Growth | +11.62% | -1,269.23% | +105.09% | -54.47% | +38.85% |
Freeline Therapeutics Holdings Plc Adss (FRLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Freeline Therapeutics Holdings plc is a clinical-stage biotechnology company. It is focused on AAV-based gene therapy targeting the liver. The company operates principally in Germany and the U.S. Freeline Therapeutics Holdings plc is headquartered in the U.K.
Fiscal Year End Date: 12/31